COMP <GO>
IMCR vs NVAX // OPERATING MARGIN
Immunocore Holdings plc (NASDAQ) VS. Novavax Inc. (NASDAQ) • 15-METRIC TALLY: IMCR 4
— NVAX 5
▲ OPERATING MARGIN LEADER: NVAX
LAST: $30.49 (-2.49%) • MKT CAP: $1.61B
operating-margins
-11.30%
LAST: $10.08 (-3.72%) • MKT CAP: $1.73B
operating-margins
40.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMCR VS. NVAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMCR | NVAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 93.50% | +2.50 | IMCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 85.00% | -120.00 | NVAX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 3.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.93% | -14.17% | +13.24 | IMCR | /fcf-yield <GO> |
| Operating Margin ACTIVE | -11.30% | 40.30% | -51.60 | NVAX | /operating-margins <GO> |
| Net Profit Margin | -8.90% | 39.20% | -48.10 | NVAX | /net-margins <GO> |
| Revenue Growth (YoY) | 29.00% | 64.70% | -35.70 | NVAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.40 | 0.20 | +1.20 | IMCR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.8 | 48.3 | +2.50 | IMCR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 3.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $1.73B | -$116.6M | NVAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMCR REV | NVAX REV | IMCR GROSS % | NVAX GROSS % | IMCR FCF | NVAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $400.0M | $1.12B | 98.0% | 93.5% | -$15.1M | -$244.6M |
| FY 2024 | $310.2M | $682.2M | 98.0% | 70.3% | $20.9M | -$87.3M |
| FY 2023 | $249.4M | $983.7M | — | — | $2.9M | -$714.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMCR // BETA —
NVAX // BETA —